The health ministry is expected to cut the official price of the drug by up to 15% from the current level of about ¥3 million ...

We spoke to the first author of a new study that could challenge much of what we thought we knew about Alzheimer’s disease.

Two breakthrough Alzheimer's drugs have been deemed far too expensive, for too little benefit, to be offered on the NHS. The ...

Dr. Nicholas Milano of Medical University of SC says medications such as Lecanemab and donanemab give Alzheimer's patients new hope through MUSC's SCAN program ...

Treating the neurodegenerative disease in its earlier stages is key to slowing cognitive decline. A new study offers hope for the future.

Eli Lilly has won a green light from the FDA for new dosing for its Alzheimer's disease therapy Kisunla, which carries a ...

A recent study of patients who developed bipolar disorder or depression later in life revealed that half had high ...

A promising new study from the Knight Family DIAN-TU research group at Washington University School of Medicine has found that starting Alzheimer’s treatment years before symptoms begin could delay — ...

The New York Times ran a lengthy interview this morning between columnist Ross Douthat and venture capitalist and PayPal ...

Drugs that slow progression of Alzheimer’s don’t provide enough benefit to justify substantial cost for NHS, regulator has said ...

With promising drugs in the pipeline, we are on the cusp of "turning the tide" against Alzheimer's. But President Trump's plan to slash research spending could delay or halt progress for years, ...

NICE said it made every effort to support reimbursement for Kisunla and Leqembi, but found the medicines are “not good value for money”.